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Abstract
The purpose of the study was to evaluate the efficacy of an extract of Panax ginseng 
in patients with fibromyalgia. A randomized, double-blind, controlled clinical trial 
was carried out over 12 weeks to compare the effects of P. ginseng (100 mg/d) with 
amitriptyline (25 mg/d) and placebo in 38 patients with fibromyalgia: 13 in Group I 
(amitriptyline), 13 in Group II (placebo), and 12 in Group III (P. ginseng). Ratings on the Visual 
Analogue Scale (VAS) revealed a reduction in pain in the P. ginseng group (p < .0001), an 
improvement in fatigue (p < .0001) and an improvement in sleep (p < .001), with respect to 
baseline characteristics, but there were no differences between the three groups. With respect 
to anxiety, improvements occurred in the P. ginseng group compared to baseline (p < .0001); 
KRZHYHU DPLWULSW\OLQH WUHDWPHQW UHVXOWHG LQ VLJQLÀFDQWO\ JUHDWHU LPSURYHPHQWV S   
P. ginseng reduced the number of tender points and improved patients’ quality of life (using the 
Fibromyalgia Impact Questionnaire - FIQ); however, there were no differences between groups. 
7KHEHQHÀFLDOHIIHFWVH[SHULHQFHGE\SDWLHQWVIRUDOOSDUDPHWHUVVXJJHVWDQHHGIRUIXUWKHU
VWXGLHVWREHSHUIRUPHGRQWKHWROHUDELOLW\DQGHIÀFDF\RIWKLVSK\WRWKHUDSLFDVDFRPSOHPHQWDU\
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,QWURGXFWLRQ
Fibromyalgia is a chronic pain syndrome that affects up to 5% 
of the population worldwide. Clinically, it is characterized 
by the presence of diffuse pain and hypersensitive points 
detected through physical examination and generally ac-
companied by fatigue, sleep and mood disorders.1 Although 
LWVSDWKRJHQHVLVKDV\HW WREH IXOO\FODULÀHGPRVWRI WKH
evidence points to a disorder of central pain modulation, 
impairments of the descending inhibitory system (serotonin-
ergic, noradrenergic and opioid) and/or hyperactivity of 
excitatory neurotransmitters such as substance P.2
7UHDWPHQWRIÀEURP\DOJLDLQFOXGHVERWKQRQSKDUPDFR-
logical therapies and pharmacological interventions. Many 
patients respond well to exercise,3 and up to 50% of cases 
respond adequately to treatment with tricyclic antidepressants 
such as low-dose amitriptyline.4 Various other drugs used in 
controlled studies have been found to relieve the symptoms of 
ÀEURP\DOJLDLQFOXGLQJÁXR[HWLQH5 duloxetine,6 milnacipran,7 
cyclobenzaprine,8 gabapentin,9 pregabalin10 and tramadol.11 
Patients are, however, extremely interested in alternative and 
complementary medicine for the treatment of this disease.12 
Panax ginseng C.A. Meyer is an herb that has been used 
for hundreds of years in Eastern medicine.13 The principal 
active components of P. ginseng are the ginsenosides or 
triterpenoid saponins of ginseng, and approximately 38 
W\SHVRIJLQVHQRVLGHVKDYHEHHQLGHQWLÀHG14 Some experi-
mental studies have suggested that ginsenosides act on the 
central nervous system, particularly in neurodegenerative 
disorders.15 Ginsenoside Rg3 has been reported to inhibit 
glutamate receptors (N-methyl-D-aspartate (NMDA) type 
DQG QRQ10'$ZKLFK FRQWULEXWH VLJQLÀFDQWO\ WR WKH RF-
currence of brain trauma and convulsions.16 Various stud-
ies have demonstrated the antinociceptive effects of 
P. ginseng in vitro and in vivo.17-19 Shin et al.17 demonstrated a 
central effect of ginsenosides, but there was no effect on 
peripheral nociceptors. The ginsenoside Rg3 inhibited calcium 
channels in the neurons of the dorsal spine region18 and intra-
peritoneal administration of the extract provoked an analgesic 
effect, most likely as the result of a nonopioid mechanism.19
No clinical studies have been carried out to evaluate the 
effect of P. ginseng on chronic pain. 
The objective of the present study is to evaluate 
WKHWKHUDSHXWLFHIÀFDF\RIP. ginseng root extract on the 
FRQWURORIV\PSWRPVLQSDWLHQWVZLWKÀEURP\DOJLD
0HWKRGV
Subjects
)LIW\WZR SDWLHQWVZLWK D GLDJQRVLV RI ÀEURP\DOJLD GLDJ-
QRVHG DFFRUGLQJ WR WKH FULWHULD GHÀQHG E\ WKH$PHULFDQ
College of Rheumatology (ACR),1 who were receiving care 
at the Rheumatology Outpatient Clinic of the Center for 
Rheumatology, Physical Medicine and Motor Rehabilitation 
in the city of Santa Rita, Paraíba, Brazil, between February 
2008 and May 2009, were selected and invited to participate 
as volunteers in the study. The study population consisted 
of women spontaneously attending the clinic or referred by 
the various units comprising the Santa Rita public health-
care system following an announcement of the study to the 
physicians in the city. Men were not included in the study 
EHFDXVHRIWKH ODFNRIFRQWUROOHGVFLHQWLÀFVWXGLHVRIWKH
FOLQLFDOFKDUDFWHULVWLFVDQGVHYHULW\RIÀEURP\DOJLDLQPHQ
The following admission criteria were used to screen 
patients for the study: 1) women aged 21 to 60 years of any 
HWKQLFRULJLQZLWKDGLDJQRVLVRIÀEURP\DOJLD$&51 
who were examined at the rheumatology outpatient clinic 
by a single examiner; and 2) patients whose laboratory tests 
(complete blood count, erythrocyte sedimentation rate, cre-
atine, aminotransferases and thyroid stimulating hormone) 
were all within the normal range.
Candidates with the following characteristics were excluded 
IURPWKHVWXG\SDWLHQWVZLWKDGLDJQRVLVRIXQWUHDWHGLQÁDP-
matory rheumatic or endocrine disease and/or neurological, 
renal, infectious or bone disease; patients with glaucoma, 
urinary retention, coronary heart disease, arrhythmias or con-
gestive heart failure, and pregnant or breastfeeding women; 
2) patients who had used tricyclic antidepressants in the previ-
ous three months; 3) patients hypersensitive to ginseng or its 
components, patients with hemorrhages, high estrogen levels or 
undergoing hormone treatment; and 4) patients taking steroids 
or antipsychotic drugs contraindicated for use with ginseng. 
Prior to initiation of the study, the patients who used analgesics, 
RSLRLGVRUDQWLLQÁDPPDWRU\GUXJVZHUHUHTXLUHGWRVWRSXVLQJ 
the medication for at least three weeks.
Drugs
The pharmacologically evaluated compounds used in the 
study were as follows: amitriptyline hydrochloride (25 mg/d), 
P. ginseng root extract (100 mg/d - 27% of ginsenosides) and 
placebo (talcum powder) and were prepared in identical 
form as capsules and provided to the patients in sealed, 
black bottles. All were supplied by Orient Mix Fitoterápicos 
do Brasil Ltda. Staff were blind with respect to the medica-
tion, and the patients were divided into three groups: Group 
I (amitriptyline), Group II (placebo) and Group III (P. ginseng).
Study design
The study consisted of a randomized, double-blind, con-
trolled, 12-week clinical trial to compare the treatment of 
ÀEURP\DOJLDZLWKDPLWULSW\OLQHP. ginseng and placebo. The 
patients were randomized into three groups in a proportion of 
1:1:1 to receive one of the three types of medication, which 
they were instructed to take as a single daily dose, always at 
6 p.m. After receiving the capsules on day zero (baseline), 
the patients returned for follow-up one week later and every 
three weeks thereafter for a total of six visits (0, 1, 3, 6, 9 
and 12 weeks). At each follow-up visit, patients underwent 
a specialized physical examination. In addition, they were 
asked whether their symptoms had improved, whether they 
KDGUHPDLQHGWKHVDPHRUZKHWKHUWKH\KDGLQWHQVLÀHGLQDF-
FRUGDQFHZLWKDSURWRFROVSHFLÀFDOO\GHVLJQHGIRUWKLVVWXG\
The study was conducted according to the directives and 
regulations governing research studies involving human beings, 
DVGHÀQHGLQ5HVROXWLRQVDQGRIWKH%UD]LOLDQ
Ministry of Health’s National Health Council. The protocol was 
approved by the Internal Review Board of the Lauro Wanderley 
Teaching Hospital, Universidade Federal da Paraíba on October 
30, 2007, under protocol number 085/05. Patients were in-
formed of the nature and objectives of the study and were 
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admitted only after they had signed an informed consent form 
LQGXSOLFDWHWKHUHE\FRQÀUPLQJDJUHHPHQWWRSDUWLFLSDWHLQ
the study and authorizing publication of the results. 
Clinical assessment 
The Visual Analog Scale (VAS) was used to evaluate pain, 
fatigue, sleep quality and anxiety and was completed by all 
patients. It consists of a line extending from 0 to 10 cm on 
which the patient attributes a value for any given variable at 
the time of evaluation. Zero represents the absence of that 
variable and 10 the maximum intensity reported.
During physical examination, a simple count of ten-
der points was made by digitally palpating the region 
with an approximate pressure of 4 kgf/cm2.20 The sites 
SDOSDWHGZHUH WKRVH GHÀQHG E\ WKH$&51 The test was 
considered positive when the patients reacted in any of the 
following three ways after application of digital pressure: 
1) involuntary verbal indication of pain; 2) facial expression 
RISDLQFRQÀUPHGE\WKHLQYHVWLJDWRU·VTXHVWLRQLQJDQG
RULIWKHSDLQZDVFDSDEOHRIPDNLQJWKHSDWLHQWÁLQFKRU
remove the investigator’s hand.
The quality of life of the patients in this study was 
evaluated using the Fibromyalgia Impact Questionnaire 
),4DGLVHDVHVSHFLÀFTXHVWLRQQDLUHLQLWLDOO\SURSRVHGE\
Burckhardt et al.21 for the evaluation of quality of life in 
SDWLHQWVZLWKÀEURP\DOJLD,WZDVYDOLGDWHGIRUXVHLQWKH
Brazilian population by Marques et al.22 This questionnaire 
LVFRPSRVHGRIGRPDLQVWKHÀUVWFRQVLVWLQJRIVXE
items or questions and the other nine of only one question 
HDFK7KHÀUVWGRPDLQFRQWDLQVTXHVWLRQVFRQFHUQLQJWKH
capacity of the patient to perform certain routine activi-
ties. Responses range from 0, always able to perform the 
activity, to 3, never able to perform the activity. Item two 
refers to the number of days during which the patient felt 
well in the previous week and item three to the number 
of days on which the patient was unable to go to work 
because of the disease. Possible answers range from 0 
to 7 for each item or domain. For domains 4-10, scores 
UDQJHIURPWRLQHDFK7KHVHÀQDOVHYHQLWHPVDUH
designed to collect data on the patient’s capacity to work 
and their perceptions of pain, fatigue, morning stiffness, 
mood, anxiety and depression. The data from the FIQ are 
arranged so that no more than 10 points can be scored for 
any single item. Items 2 and 3 are considered inversely 
proportional; therefore, the maximum possible score in 
this questionnaire will generally be 100.
Statistical analysis 
Descriptive analyses were performed to obtain the frequency 
distributions of the nominal variables, as well as the means 
and standard error of the numerical variables. Comparative 
analyses between the variables were performed using 
the Friedman test to evaluate inter- and intragroup differ-
ences in variances. Next, Dunn’s test was applied to deter-
PLQHZKHWKHUGLIIHUHQFHVZHUHVWDWLVWLFDOO\VLJQLÀFDQWDQG
whether there was a difference between the three treatment 
groups. The results were analyzed using the Graph Pad Prism 
VRIWZDUHSDFNDJHYHUVLRQDQGVWDWLVWLFDOVLJQLÀFDQFH
ZDVGHÀQHGDVS
5HVXOWV
Clinical and demographic data 
Fifty-two patients were enrolled in the study, 16 in Group I 
(amitriptyline), 17 in Group II (placebo) and 19 in 
Group III (P. ginseng). Nevertheless, only 38 patients com-
pleted the entire 12-week follow-up period (13 in Group 
I, 13 in Group II and 12 in Group III). Of the 14 patients 
who failed to complete the study, the three in Group I 
GURSSHG RXW LQ WKH ÀUVWZHHN RI IROORZXS WZR EHFDXVH
of side effects), and one returned in the third week. Of 
the four patients who discontinued in Group II, three 
GURSSHGRXW LQWKHÀUVWZHHNFRPSODLQLQJRIYDULRXVVLGH
effects and one abandoned the study because she moved 
away. In Group III, seven patients dropped out; three 
reported various side effects, two dropped out in the 
third week without giving any reason, and two abandoned 
the study because of lack of time to attend consultations or 
GLIÀFXOWLHVLQDWWHQGLQJWKHFOLQLF
The study sample was composed of women 27-58 years of 
age (mean 43.2 years) who had had the disease for a mean 
duration of 43.8 months. Of the 38 patients, 19 (50%) were cur-
rently employed, while 18 (47.4%) had no paid employment and 
RQHZDVRQVLFNOHDYH7KHUHZHUHQRVWDWLVWLFDOO\VLJQLÀFDQW
differences between the three groups with respect to their 
baseline epidemiological or clinical characteristics (Table 1).
(IÀFDF\RI3JLQVHQJXVLQJ9$6
3DLQ Reductions in mean pain scores were found in the group 
that used P. ginseng (F(5) = 8.8; p < .0001), and Dunn’s test 
showed that these differences were present from the sixth 
week on when compared to pretreatment scores. There were 
reductions of 31.7% in mean pain scores at the sixth week 
(p < .001), of 35.6% at the ninth week and of 39.4% at 
the 12th week (p < .001) of follow-up compared to baseline 
values. In the amitriptyline group, reductions were also 
found in mean pain scores (F(5) = 8.8; p < .001). Post-tests 
indicated that these reductions occurred from the third week 
on (p < .05), with reductions in pain of 25.4% at the 3rd 
week, 30.1% at the 6th week (p < .01), 37.2% at the 9th week 
(p < .001) and 44.6% at the 12th week of treatment (p < .001). 
6WDWLVWLFDOO\VLJQLÀFDQWGLIIHUHQFHVDOVRRFFXUUHGLQWKHJURXS
of women who received placebo (F(5) = 8.7; p < .001) at the 
ninth and twelfth weeks of evaluation, with reductions of 
35.7% (p < .01) and 48% (p < .001), respectively (Figure 1). 
After applying Dunn’s test for multiple comparisons of mean 
improvement in the scores of the three groups, no statisti-
FDOO\VLJQLÀFDQWGLIIHUHQFHVZHUHIRXQGEHWZHHQWKHJURXSV
(F(2) = .2; p > .05).
)DWLJXH7KHUHZHUHVWDWLVWLFDOO\VLJQLÀFDQWUHGXFWLRQV
in the mean scores for fatigue in the group that received 
P. ginseng (F(5) = 8.9; p < .001). Dunn’s test indicated statisti-
FDOO\VLJQLÀFDQWGLIIHUHQFHVLQFRPSDULVRQZLWKSUHWUHDWPHQW
values at the third week (25.9% of improvement; p < .05), 
sixth week (24.7%; p < .05); ninth week (39.3%; p < .001) and 
12thZHHNRIIROORZXSS6LJQLÀFDQWGLIIHU-
ences were also found in the amitriptyline group (F(5) = 5.9; 
SZLWKVLJQLÀFDQWUHGXFWLRQVLQIDWLJXHUHFRUGHGDW
week 6 (30.8%; p < .01), 9 (34.5%; p < .01) and 12 (38.7%; 
SFRPSDUHGWREDVHOLQHYDOXHV6WDWLVWLFDOO\VLJQLÀFDQW
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differences were also found in the group of women who re-
ceived placebo (F(5) = 16.7; p < .001). Post-tests showed an 
improvement at the 3rd week (24.2% improvement; p < .01), 
6th week (28.3%; p < .001), 9th week (40.3%; p < .001) and 12th 
week of evaluation (51.5%; p < .001) (Figure 2). After cor-
rection for multiple comparisons, there were no statistically 
VLJQLÀFDQWGLIIHUHQFHV LQ LPSURYHPHQWEHWZHHQWKHPHDQ
scores of the three groups (F(2) = .9; p > .05).
6OHHSTXDOLW\ In evaluations of sleep quality, statisti-
FDOO\ VLJQLÀFDQW UHGXFWLRQVZHUH IRXQG LQ WKHPHDQ VOHHS
scores of the patients treated with P. ginseng (F(5) = 5.7; 
p < .001). These differences were also found at weeks 6 
(p < .01), 9 (p < .01) and 12 (p < .01), with an improvement 
in sleep quality of 42%, 44.3% and 44.3%, respectively, when 
compared to baseline data. In the patients treated with 
amitriptyline, improvements were found in the mean scores 
IRUVOHHSTXDOLW\) SLQWKHÀUVWZHHNRI
treatment (43.3%; p < .05) and at weeks 3 (45.7%; p < .01), 
6 (53.3%; p < .001), 9 (55.9%; p < .001) and 12 (54.6%; 
p < .001). Improvements in patients who received placebo 
ZHUHDOVRVWDWLVWLFDOO\VLJQLÀFDQW) SDV
shown at weeks 1 (21.6% of improvement; p < .05), 3 (29.5%; 
p < .001), 6 (32.9%; p < .001), 9 (49.9%; p < .001) and 12 
(61.3%; p < .001) compared to baseline data (Figure 3). 
7DEOHEpidemiological and clinical characteristics at baseline, according to the treatment group.
$PLWULSW\OLQHQ  3ODFHERQ  P. ginsengQ 
Age (years) 44.3  2.0 41.6  2.5 43.6  2.2
Education level (years of schooling) 8.3  1.0 8.5  1.2 10.0  .9
'XUDWLRQRIÀEURP\DOJLDPRQWKV 40.9  9.6 33.2  9.1 58.3  13.2
Duration (months) of
 Pain 37.5  10.0 27.2  6.4 54.3  13.7
 Fatigue 23.1  5.8 25.6  4.5 48.4  12.2
 Sleep disturbances 11.4  3.1 26.1  9.6 33.1  11.2
 Anxiety 24.5  8.9 37.1  6.9 42.1  12.6
VAS score for*
 Pain 9.0 (7.3-9.6) 8.0 (5.7-9.3) 9.0 (7.7-9.6)
 Fatigue 8.0 (4.8-8.6) 8.0 (6.4-8.8) 8.5 (6.5-9.7)
 Sleep disturbances 7.0 (4.2-7.9) 8.0 (4.7-8.8) 8.5 (5.3-9.4)
 Anxiety 7.0 (2.9-8.0) 9.0 (5.8-9.5) 9.0 (5.5-9.4)
Positive tender points 16 (14-17) 15 (14-17) 15.5 (14-17)
FIQ 50 (48-59) 54 (44-61) 58 (47-67)
$OOGDWDDUHVKRZQDVWKHPHDQVWDQGDUGHUURU'DWDDUHVKRZQDVPHGLDQFRQÀGHQFHLQWHUYDOV9$69LVXDO$QDORJ6FDOH),4)LEURP\DOJLD,PSDFW
Questionnaire.
)LJXUH  Effects of amitriptyline (n = 13), placebo (n = 13) and 
P. ginseng (n = 12) on pain according to VAS score. Data are expressed as the 
mean ± standard error of the mean compared with baseline data. Friedman 
followed by Dunn’s test. * p < .05; ** p < .01; *** p < .001.
)LJXUH  Effects of amitriptyline (n = 13), placebo (n = 13) and 
P. ginseng (n = 12) on fatigue according to VAS score. Data are expressed as the 
mean ± standard error of the mean compared with baseline data. Friedman 
followed by Dunn’s test. * p < .05; ** p < .01; *** p < .001.
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After correction for multiple comparisons, there were no 
VWDWLVWLFDOO\ VLJQLÀFDQWGLIIHUHQFHVEHWZHHQWKHPHDQ LP-
provement scores in the three groups (F(2) = 2.6; p > .05).
$Q[LHW\ There were reductions in mean anxiety 
scores in the group of women who received P. ginseng 
(F(5) = 8.1; p < .001), as shown in the 9th week (44% im-
provement; p < .05) and in the 12th week of treatment (a 
55.6% reduction in anxiety; p < .001). In the patients who 
ZHUHJLYHQDPLWULSW\OLQHVLJQLÀFDQWLPSURYHPHQWVZHUH
found in anxiety (F(5) = 7.0; p < .001), as shown at weeks 
3 (43.7% improvement; p < .001), 6 (49.3%; p < .01), 9 
(52.0%; p < .001) and 12 (49.3%; p < .001). In the placebo 
group, differences were also found in mean anxiety scores 
)    S  ZLWK D VLJQLÀFDQW LPSURYHPHQW
occurring at weeks 3 (23.9%; p < .05), 6 (26.9%; p < .01), 
9 (37.97%; p < .001) and 12 (49.0%; p < .001) compared to 
baseline values (Figure 4). After correction for multiple 
comparisons between the mean scores of the three groups 
(at six weeks of the study), there was a statistically sig-
QLÀFDQWLPSURYHPHQWLQDQ[LHW\LQWKHDPLWULSW\OLQHJURXS
compared to the placebo and P. ginseng groups (F(2) = 5.6; 
p < .05): amitriptyline versus placebo (difference in means: 
-2.3; p < .05); amitriptyline versus P. ginseng (-2.5; p < .05) 
and placebo versus P. ginseng (-.2; p > .05).
(IÀFDF\RIP. ginseng using tender point count
A simple tender point count was performed in the three 
groups, with improvements found in the mean scores of 
all three groups compared to baseline (Figure 5). In the 
patients who received P. ginseng, there was a reduction in 
the number of tender points (F(5) = 14.1; p < .001). These 
improvements were detected with Dunn’s test at weeks 3 
(21.1% improvement; p < .01), 6 (31.9%; p < .001), 9 (33.5%; 
SDQGS6WDWLVWLFDOO\VLJQLÀFDQW
improvements also occurred in the group that received ami-
triptyline (F(5) = 11.1; p < .001), as shown at the 3rd week 
(33.7% improvement; p < .001), 6th week (30.6%; p < .01), 
9th week (37.7%; p < .001) and 12th week (41.7%; p < .001). 
6WDWLVWLFDOO\VLJQLÀFDQWLPSURYHPHQWVZHUHDOVRIRXQGLQWKH
placebo group (F(5) = 12.8; p < .001) at weeks 6 (21.5% im-
provement; p < .05), 9 (29%; p < .001) and 12 (45%; p < .001). 
After correction for multiple comparisons of the mean num-
ber of tender points between the three groups, there were 
QRVWDWLVWLFDOO\VLJQLÀFDQWGLIIHUHQFHV) S!
)LJXUH  Effects of amitriptyline (n = 13), placebo (n = 13) and 
P. ginseng (n = 12) on sleep quality according to VAS score. Data are expressed as 
the mean ± standard error of the mean compared with baseline data. Friedman 
followed by Dunn’s test. * p < .05; ** p < .01; *** p < .001.
)LJXUH  Effects of amitriptyline (n = 13), placebo (n = 13) and 
P. ginseng (n = 12) on anxiety according to VAS score. Data are expressed 
as the mean ± standard error of the mean compared with baseline data. 
Friedman followed by Dunn’s test. * p < .05; ** p < .01; *** p < .001.
)LJXUH  Effects of amitriptyline (n = 13), placebo (n = 13) and 
P. ginseng (n = 12) on pain according to tender point count. Data 
are expressed as the mean ± standard error of the mean compared 
with baseline data. Friedman followed by Dunn’s test. * p < .05; 
** p < .01; *** p < .001.
(IÀFDF\RI3JLQVHQJRQTXDOLW\RIOLIHXVLQJWKH),4
6WDWLVWLFDOO\VLJQLÀFDQWLPSURYHPHQWVLQTXDOLW\RIOLIHZHUH
found in all three groups (Figure 6). In the patients using P. 
ginsengVLJQLÀFDQWUHGXFWLRQVRFFXUUHGLQPHDQWRWDO),4
scores (F(5) = 6.3; p < .001) at weeks 9 (38.2% improvement; 
p < .01) and 12 (48.3%; p < .001). In the amitriptyline group, 
WKHUHZHUH VWDWLVWLFDOO\ VLJQLÀFDQW LPSURYHPHQWV LQPHDQ
total FIQ scores (F(5) = 3.0; p < .05) at weeks 9 (39.3%; 
p < .05) and 12 (40.9%; p < .05). In the patients who received 
placebo, improvements were found in mean total FIQ scores 
(F(5) = 3.8; p < .01) at week 12 (38.7%; p < .01). After cor-
rection for multiple comparisons of the mean FIQ scores, 
WKHUHZHUHQRVWDWLVWLFDOO\VLJQLÀFDQWGLIIHUHQFHVEHWZHHQ
the three groups (F(2) = .3; p > .05).
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'LVFXVVLRQ
In this randomized, double-blind, 12-week trial, P. ginseng 
&$0H\HUZDVXVHGWRWUHDWÀEURP\DOJLD7KLVSK\WRWKHUD-
pic is commercially available worldwide, and in Oriental 
medicine, it is primarily indicated for fatigue and weakness. 
Recently, P. ginseng has become well-known in Europe and 
in the United States for its effects on multiple organs 
and systems, particularly in the control of organic homeo-
stasis.23 Nevertheless, although the substance is popularly 
indicated for the treatment of chronic pain and fatigue, no 
studies have yet been conducted on the use of P. ginseng for 
WKHWUHDWPHQWRIÀEURP\DOJLD
The analgesic effects of P. ginseng have yet to be evalu-
ated in clinical studies. Its antinociceptive effects have been 
demonstrated in previous preclinical studies.17 The inhibitory 
effects of ginsenosides on substance P-induced pain and the 
capacity of this substance to inhibit calcium channels in 
GRUVDOVSLQDOQHXURQVKDYHEHHQFRQÀUPHG18 The effects of 
P. ginseng on pain (evaluated by the VAS) were not different 
from the effects achieved with the other therapies used in 
this study.
Based upon these data, the authors believe that the posi-
tive effects on pain obtained with P. ginseng may be associ-
ated with one or both of the aforementioned pharmacological 
effects. The effects of amitriptyline in the patients in the 
present sample occurred from the 3rd week on, which was 
expected because this drug has been used successfully at 
doses of 12.5 to 50 mg/d to treat chronic neuropathic pain 
DQGÀEURP\DOJLD8,24 
The VAS evaluation of fatigue revealed an improvement 
in the patients in the study compared to baseline data, be-
ginning in the 3rd week of therapy with P. ginseng; however, 
there was no difference between the groups.
7KHSUHVHQWVWXG\LVWKHÀUVWWRHYDOXDWHWKHHIIHFWVRI
P. ginsengRQIDWLJXH LQSDWLHQWVZLWKÀEURP\DOJLD ,QWKH
group receiving amitriptyline, contrary to its effects on pain, 
WKHGUXJRQO\DIIHFWHGIDWLJXHVLJQLÀFDQWO\DIWHUVL[ZHHNV
of therapy (i.e., the improvement in fatigue found in the 
P. ginsengJURXSDOWKRXJKQRWVLJQLÀFDQWO\GLIIHUHQWIURPWKH
improvement achieved by the other two groups, occurred 
earlier than the improvement with the standard drug used 
for the treatment of this disease). Our data support conclu-
sions reached in a meta-analysis conducted by Häuser et al.4 
In this meta-analysis, strong evidence was found against 
the use of amitriptyline and duloxetine for the treatment 
RIIDWLJXHLQÀEURP\DOJLD
There were no differences between the three groups in 
sleep quality. There are no studies in the literature evaluating 
the effects of P. ginseng on sleep. It is known that tricyclic 
antidepressants tend to improve the quality and depth of 
VOHHS LQSDWLHQWVZLWKÀEURP\DOJLD247KHVHÀQGLQJVZHUH
FRQÀUPHGLQWKHSUHVHQWVWXG\LQZKLFKDQLPSURYHPHQWLQ
sleep occurred earlier in the amitriptyline group.
$Q[LHW\ZDVGHÀQHGSULRUWRDSSOLFDWLRQRIWKH LQVWUX-
ment as a state of mild uneasiness or apprehension. More 
VSHFLÀFHYDOXDWLRQPHWKRGVIRUDQ[LHW\DQGRUGHSUHVVLRQ
such as the Hospital Anxiety and Depression Scale or the Beck 
Depression Inventory, were not used. In this study, P. ginseng 
effectively reduced anxiety by the 9th week of therapy (VAS), 
whereas an improvement was observed in both the placebo 
and amitriptyline groups by the 3rd week. 
A randomized, controlled, double-blind study was 
conducted in which the effects of the phytotherapeutic 
substance Hypericum perfuratum were compared with the 
HIIHFWVRIDPLWULSW\OLQHIRUWKHWUHDWPHQWRIÀEURP\DOJLD$V
HYDOXDWHGDFFRUGLQJWRWKH9$6DQG),4VLJQLÀFDQWLPSURYH-
ments occurred in both groups when compared with baseline 
data.25,QDJUHHPHQWZLWKWKHÀQGLQJVRIWKHVWXG\FRQGXFWHG
with H. perfuratum, treatment with P. ginseng resulted in an 
improvement in anxiety compared to pretreatment values; 
however, when the three groups were compared (ANOVA on 
six weeks of the study), amitriptyline was found to be more 
effective than the other treatments. Contrary to the present 
study, in the previous clinical trial, there was no placebo 
group and the Beck Depression Inventory was used. 
Another important pain evaluation instrument used to 
DVVHVVSDWLHQWVZLWKÀEURP\DOJLDLVWKHWHQGHUSRLQWFRXQW
In the present study, there was a reduction in tender point 
count compared to baseline values in all three groups. A study 
similar to the present trial evaluated Chorella pyrenoidosa 
JUHHQDOJDHLQSDWLHQWVZLWKÀEURP\DOJLDDQGDOVRXVHGWKH
tender point count as one of the pain assessment instruments. 
7KHVHDXWKRUVUHSRUWHGDVLJQLÀFDQWUHGXFWLRQLQWKHQXPEHU
of tender points in the patients treated with C. pyrenoidosa 
compared to the placebo group.26
The importance of the tender point count in the diagnosis 
RIÀEURP\DOJLDUHPDLQVDVXEMHFWRIGHEDWH LQWKH OLWHUD-
ture.20 Moreover, the authors agree with Harth and Nelson27 
that abandoning the tender point count may mean a return 
to the diagnostic dilemma prevalent prior to the establish-
ment of the ACR criteria.
The quality of life and functional capacity of patients with 
ÀEURP\DOJLD KDYH EHHQ HYDOXDWHG XVLQJ YDULRXV TXHVWLRQ-
naires that allow a more objective evaluation of subjective 
symptoms such as pain, anxiety, depression and general 
well-being, among others. Burckhardt et al.21 proposed and 
tested the use of an instrument for evaluating quality of life 
WKDWZDVGHYHORSHGVSHFLÀFDOO\IRUXVHLQSDWLHQWVZLWKÀEUR-
myalgia, the FIQ. According to these authors, the maximum 
SRVVLEOHVFRUHLQSDWLHQWVZLWKÀEURP\DOJLDLVDQGWKH
PHDQVFRUHIRXQGLQSDWLHQWVZLWKÀEURP\DOJLDLVDSSUR[L-
mately 50. Patients whose quality of life is strongly affected 
)LJXUH  Effects of amitriptyline (n = 13), placebo (n = 13) and 
P. ginseng (n = 12) on quality of life according to the FIQ. Data are 
expressed as the mean ± standard error of the mean compared 
with baseline data. Friedman followed by Dunn’s test. * p < .05; 
** p < .01; *** p < .001.
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JHQHUDOO\VFRUH7KHSDWLHQWVLQWKHSUHVHQWVWXG\KDG
mean baseline scores of 54, 52 and 55 for the amitriptyline, 
placebo and P. ginseng groups, respectively.
The FIQ was tested and validated in Brazil by Marques 
et al.22 who considered it valid and reliable for the measure-
ment of the functional capacity and health status of Brazilian 
ÀEURP\DOJLDSDWLHQWV:HXVHGWKLVLQVWUXPHQWLQRXUVWXG\
EHFDXVHWKHTXHVWLRQQDLUHZDVVSHFLÀFDOO\GHVLJQHGIRUXVH
LQÀEURP\DOJLDDQGKDGDOUHDG\EHHQXVHGLQYDULRXVVWXGLHV
of the disease.
Coleman et al.28 performed a meta-analysis of the use of 
P. ginseng to improve quality of life. They evaluated nine clinical 
trials, eight of which were placebo-controlled. Of these, the 
doses of P. ginseng used varied from 80 to 400 mg/d. 
The different studies ranged from 2 to 9 months in duration 
and evaluated quality of life in various sample populations: 
type II diabetes mellitus, menopausal women, patients with 
PHPRU\LPSDLUPHQWDQGKHDOWK\YROXQWHHUV1RVLJQLÀFDQW
differences in responses were found between the different 
doses used, either when P. ginseng was prescribed alone or 
together with vitamins and/or mineral salts. According to 
Coleman, the majority of studies of the effect of P. ginseng 
RQTXDOLW\RI OLIHIDLOHGWRVKRZDQ\LPSURYHPHQWLQÀQDO
scores with the use of this plant substance; however, the 
possibility that improvement in some parameters of quality 
of life may have been related to its use cannot be discarded.28 
Comparisons of these data with those from the present study 
DUHGLIÀFXOWEHFDXVHWKHHYDOXDWLRQLQVWUXPHQWVXVHGZHUH
different and there are no other placebo-controlled clinical 
trials on the use of P. ginsengLQSDWLHQWVZLWKÀEURP\DOJLD
In a study to compare the effects of H. perfuratum with 
WKRVHRIDPLWULSW\OLQHIRUWKHWUHDWPHQWRIÀEURP\DOJLDVLJ-
QLÀFDQWLPSURYHPHQWVLQTXDOLW\RIOLIHFRPSDUHGWREDVHOLQH
were found in patients in both the treatment and control 
groups.25 In the present study, total FIQ scores improved in 
the P. ginseng group as well as in the placebo and amitripty-
line groups. The percentage of patients who improved with 
P. ginseng was higher than the percentages in the placebo and 
amitriptyline groups at the 12th week of treatment, although 
WKLVGLIIHUHQFHZDVQRWVLJQLÀFDQW
An important question raised by the authors concerns 
the therapeutic response obtained in the placebo. In recent 
\HDUV VFLHQWLÀF LQWHUHVW KDV JURZQ LQ XQGHUVWDQGLQJ DQG
determining the true placebo effect, principally in relation 
to the development of new drugs and/or active components. 
,QDVWXG\SXEOLVKHGWKHÀQGLQJVRIDQHYDOXDWLRQRI
the positive and negative effects of placebo on the opi-
oid and dopaminergic pathways (receptors D2 and D3) in 
men and women following a stressful situation, as measured 
by positron emission tomography. Activation of the opioid and 
dopaminergic pathways were observed in various areas of the 
brain, principally in the nucleus accumbens in this study.29
,QÀEURP\DOJLDDOWHUDWLRQVLQWKHSDLQLQKLELWLQJGHVFHQG-
ing pathways, including the serotoninergic, noradrenergic 
and possibly dopaminergic and opioid pathways, have been 
observed.5 Tramadol, an opioid analgesic, has been shown to 
H[HUWDEHQHÀFLDOHIIHFWLQSDWLHQWVZLWKÀEURP\DOJLD11 and 
a D2 and D3 dopamine receptor agonist has shown promising 
results in the treatment of this condition.30 Likewise, the pos-
sibility of the participation of a placebo in these pathways 
cannot be discarded in view of the therapeutic response 
observed in this study sample. Therefore, the response ob-
served in the placebo group in the present study may have 
occurred as a function of various other factors, including 
the sample size, the relief of symptoms after receiv-
ing attention, adequate diagnosis and treatment, a good 
doctor-patient relationship and the positive expectation of 
the patients with respect to a new treatment.
Based on the data obtained in this study, it is possible 
to conclude that the P. ginseng root extract effectively pro-
moted an improvement in pain, fatigue and sleep quality (as 
evaluated by the VAS) compared to baseline data. It was less 
effective than amitriptyline in improving patients’ anxiety, 
but it effectively reduced the number of tender points and 
improved quality of life compared to baseline values. No 
VLJQLÀFDQWGLIIHUHQFHVZHUHIRXQGEHWZHHQWKLVJURXSDQG
the groups using the other two therapeutic interventions.
Although baseline values of several variables were not 
different, especially in the group that received the P. ginseng, 
a possible interference of the evolution of symptoms during 
the study may also be considered. There were no statistically 
VLJQLÀFDQWGLIIHUHQFHVEHWZHHQWKHWKUHHJURXSVZLWKUHVSHFW
to the baseline epidemiological or clinical characteristics of 
the patients who concluded the study.
7KLVVWXG\UHSUHVHQWVWKHÀUVWVWHSLQWKHHYDOXDWLRQRIWKH
effect of P. ginseng in this group of patients. The extract was 
well-tolerated; however, further studies need to be carried out 
with larger sample sizes, with samples that include both male 
and female patients and with progressive doses to permit a bet-
WHUHYDOXDWLRQRIWKHWROHUDELOLW\DQGHIÀFDF\RIWKLVWUHDWPHQW
Following further evaluation, P. ginseng may represent an option 
for the treatment of acute and/or chronic pain and may consti-
WXWHDIXWXUHWKHUDSHXWLFRSWLRQIRUSDWLHQWVZLWKÀEURP\DOJLD
$FNQRZOHGJPHQWV
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